D
espite the availability of multiple pharmaco therapies and the known preventative effects of lifestyle modification, hypertension remains a highly prevalent disorder worldwide. Indeed, high blood pressure (BP) is estimated to result in approximately half of the global burden of all cardiovascular disease (WHO. Global health risks: mortality and burden of disease attribu table to selected major risks. WHO Press, Geneva, 2009 ). Because of the global impact of this disorder, and because of its modifiable nature, Nature Reviews Cardiology and the World Heart Federation are holding a joint session on 'Hypertension in 2012' at this year's World Congress of Cardiology in Dubai, UAE. The session will cover communitywide strategies for prevention of hyperten sion, BP measurement and targets, the latest advances in antihypertensive therapies, and management of hyper tension in the elderly. Review articles that accompany two of the talks in this session (written by the commis sioned speakers) are included in this focus issue of Nature Reviews Cardiology. An additional article that highlights the current challenges in management of this condition is also included.
As explained in Luis Ruilope's Review in this issue of Nature Reviews Cardiology, the validity of clinic BP measure ment has increasingly been questioned over the past 20-30 years, owing to increased awareness of 'whitecoat' and 'masked' hypertension. 'Whitecoat' , or 'isolated clinic' , hypertension-a condition in which patients persistently have elevated BP levels in the pres ence of a healthcare professional, but normal outof clinic BP-is thought to account for approximately onethird of all patients identified as having elevated BP in the clinic (Mancia, G. et al. Longterm risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 47, 846-853; 2006) . Clearly, a substantial proportion of patients are being incorrectly managed. In recognition of this problem and the costs associated with it, the UK's National Institute for Health and Clinical Excellence rec ommended that ambulatory BP measurement be offered to all patients with clinic BP ≥140/90 mmHg in the August 2011 update of their hypertension guidelines (National Institute for Health and Clinical Excellence. CG127 Hypertension: full guideline [online], http://www.nice. org.uk/nicemedia/live/13561/56007/56007.pdf; 2011). Encouragingly, early signs indicate that at least some UK doctors have followed this guidance; in mid March, one provider of 24h ambulatory BP monitors (Welch Allyn) reported a 350% increase in UK sales of these devices over the preceding few months.
The inverse condition to whitecoat hypertensionnormal BP in the clinic, but elevated BP when measured at home or over a 24h ambulatory period-is thought to affect approximately one in eleven patients (Mancia, G. et al. Longterm risk of mortality associated with selec tive and combined elevation in office, home and ambu latory BP. Hypertension 47, 846-853; 2006) . Known as 'masked' hypertension, this condition is associated with its own unique challenges, since clinicians are unlikely to obtain 24h ambulatory BP measurements, or even home BP measurements, for patients who present with normal BP in the clinic. Discussion and consideration of this problem are needed, particularly because masked hypertension is associated with a high prevalence of organ damage as well as increased cardiovascular risk and allcause mortality (Mancia, G. et al. Diagnosis and management of patients with whitecoat and masked hypertension. Nat. Rev. Cardiol. 8, 686-693; 2011 BP targets are another issue that has received much attention over the past few years. Multiple trials pub lished since 2009 have indicated that lowering BP to <120/80 mmHg can be dangerous in patients with estab lished cardiovascular disease and of no benefit to patients with diabetes mellitus. The current consensus seems to be that, rather than recommending that patients aim for BP <130/80 mmHg, physicians should set a BP target of 130-139/80-85 mmHg. Of course, keeping patients motivated to adhere to their antihypertensive therapeutic regimen to attain and sustain such a BP is another huge challenge that has been the focus of multiple studies over the past few years, one of which (Ogedegbe, G. O. Numerous antihypertensive pharmacotherapies are available for patients who cannot achieve their target BP by lifestyle modification alone. However, despite the abundance of choice, the current high prevalence of hypertension indicates a need for additional thera peutic strategies to be developed. As discussed by Thomas Unger and colleagues in this issue of Nature Reviews Cardiology, rather than bringing us multiple new pharmaco therapies, the past few years of research have instead provided novel fixeddose combinations of existing drugs and new nonpharmacological therapeutic strat egies. Indeed, the advent of the devicebased baro reflex activation therapy and the renal sympathetic denervation strat egy-the latter of which is actually an old idea that has been 'reincarnated' with the development of minimally invasive, catheterbased technology-are particularly exciting developments, as they might help to reduce the problem of 'treatmentresistant' hypertension. In a Research Highlight published in this issue of Nature Reviews Cardiology, we summarize the findings of a new study (Brandt, M. C. et al. Renal sympathetic denerva tion reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59, 901-909; 2012 ) that has demon strated for the first time that the beneficial BPlowering effects of renal sympathetic denervation are associated with improved cardiac function.
The prevalence of hypertension increases substan tially with age and given that the elderly proportion of the population is growing rapidly, the management of this group of patients deserves considerable attention. In their Review, Eduardo Pimenta and Suzanne Oparil discuss the common problems associated with the diag nosis and management of hypertension in the elderly, including the phenomena of 'pseudohypertension' and postural and postprandial hypotension, and the high likelihood of comorbidity and polypharmacy. They also highlight important considerations when deciding on the form of antihypertensive treatment to employ, and the latest research on how aggressively to control BP in these patients.
Studies published over the past few years have had a huge impact on the way in which clinicians are approach ing the diagnosis and management of this highly preva lent condition, and have provided much 'food for thought' for future guidelinewriting committees. We hope that you enjoy our roundup of the latest developments in clinical hypertension research. doi:10.1038/nrcardio.2012.44 
